

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claim 1. (Previously Presented) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen, isomers thereof, or mixtures thereof, as the sole anti-migraine agents.

Claim 2. (Original) The method of claim 1 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 100 to about 800 milligrams per dosage.

Claim 3. (Original) The method of claim 1 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 200 to about 600 milligrams per dose.

Claim 4. (Previously Presented) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen, isomers thereof, or mixtures thereof, as the sole anti-migraine agents.

Claim 5. (Original) The method of claim 4 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 100 to about 800 milligrams per dosage.

Claim 6. (Original) The method of claim 4 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 200 to about 600 milligrams per dose.

Claim 7. (Previously Presented) The method of claim 1 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is about 200 milligrams per dose.

Claim 8. (Previously Presented) The method of claim 1 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is about 400 milligrams per dose.

Claim 9. (Previously Presented) The method of claim 4 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is about 200 milligrams per dose.

Claim 10. (Previously Presented) The method of claim 4 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is about 400 milligrams per dose.

Claim 11. (Previously Presented) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole anti-migraine agents,

wherein the pharmaceutically acceptable salts of ibuprofen are selected from the group consisting of organic salts of ibuprofen with pharmaceutically acceptable primary, secondary, tertiary, and quaternary amines.

Claim 12. (Previously Presented) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole anti-migraine agents, wherein the pharmaceutically acceptable salt of ibuprofen is :

a) an inorganic cation salt selected from sodium, potassium, lithium, calcium, cesium, ammonia, ferrous, zinc, manganous, aluminum, ferric, and manganic;

b) an organic salt of ibuprofen with primary, secondary, tertiary and quaternary amines selected from triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procain, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, TRIS(hydroxymethyl)aminomethane, methylglycamine, theobromine, prunes, piperazine, piperidine, and polyamine resins; or

c) mixtures thereof.

Claim 13. (Previously Presented) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole anti-migraine agents, wherein the mixture is a mixture of ibuprofen and its potassium salt.

Claim 14. (Original) The method of claim 1 wherein the isomer of ibuprofen is selected from the group consisting of R-ibuprofen, S-ibuprofen and mixtures thereof.

Claim 15. (Previously Presented) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole anti-migraine agent,

wherein the pharmaceutically acceptable salts of ibuprofen are selected from the group consisting of organic salts of ibuprofen with pharmaceutically acceptable primary, secondary, tertiary, and quaternary amines.

Claim 16. (Previously Presented) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole anti-migraine agent,

wherein the pharmaceutically acceptable salt of ibuprofen is :

a) an inorganic cation salt selected from sodium, potassium, lithium, calcium, cesium, ammonia, ferrous, zinc, manganous, aluminum, ferric, and manganic;

b) an organic salt of ibuprofen with primary, secondary, tertiary and quaternary amines selected from triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procain, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, TRIS(hydroxymethyl)aminomethane,

methyleglycamine, theobromine, prunes, piperazine, piperidine, and polyamine resins; or

c) mixtures thereof.

Claim 17. (Previously Presented) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole anti-migraine agent,

wherein the mixture is a mixture of ibuprofen and its potassium salt.

Claim 18 (Original) The method of claim 4 wherein the isomer of ibuprofen is selected from the group consisting of R-ibuprofen, S-ibuprofen and mixtures thereof.

Claim 19. (Previously Presented) The method of claim 12 wherein the amount of the pharmaceutically acceptable salts of ibuprofen is from about 100 to about 1700 milligrams per dose.

Claim 20. (Previously Presented) The method of claim 16 wherein the amount of the pharmaceutically acceptable salts of ibuprofen is from about 100 to about 1700 milligrams per dose.

Claim 21. (Previously Presented) The method of claim 12 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 100 to about 1700 milligrams per dose.

Claim 22. (Previously Presented) The method of claim 12 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 200 to about 1300 milligrams per dose.

Claim 23. (Previously Presented) The method of claim 16 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 100 to about 1700 milligrams per dose.

Claim 24. (Previously Presented) The method of claim 16 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 200 to about 1300 milligrams per dose.

Claim 25. (Previously Presented) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen as the sole anti-migraine agent.

Claim 26. (Previously Presented) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:
providing an effective amount of ibuprofen as the sole anti-migraine agent.

Claims 27 – 30 (Cancelled).

Claim 31 (Previously Presented) The method of claim 1 wherein photophobia associated with migraine is treated.

Claim 32. (Previously Presented) The method of claim 1 wherein phonophobia associated with migraine is treated.

Claim 33 (New) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen as the sole anti-migraine agent to the stomach of a patient in need thereof.

Claim 34 (New) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen as the sole anti-migraine agent to the stomach of a patient in need thereof.

Claim 35 (New) A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of a composition consisting essentially of ibuprofen as the sole anti-migraine agent to the stomach of a patient in need thereof.

Claim 36 (New) A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of a composition consisting essentially of ibuprofen as the sole anti-migraine agent to the stomach of a patient in need thereof.

REMARKS